GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (MEX:BIIB) » Definitions » Net Margin %

Biogen (MEX:BIIB) Net Margin % : 17.18% (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Biogen Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Biogen's Net Income for the three months ended in Mar. 2024 was MXN6,529 Mil. Biogen's Revenue for the three months ended in Mar. 2024 was MXN38,014 Mil. Therefore, Biogen's net margin for the quarter that ended in Mar. 2024 was 17.18%.

The historical rank and industry rank for Biogen's Net Margin % or its related term are showing as below:

MEX:BIIB' s Net Margin % Range Over the Past 10 Years
Min: 11.81   Med: 30.1   Max: 40.96
Current: 12.07


MEX:BIIB's Net Margin % is ranked better than
75.2% of 1004 companies
in the Drug Manufacturers industry
Industry Median: 3.165 vs MEX:BIIB: 12.07

Biogen Net Margin % Historical Data

The historical data trend for Biogen's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Net Margin % Chart

Biogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 40.96 29.76 14.17 29.95 11.81

Biogen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.75 24.09 -2.69 10.46 17.18

Competitive Comparison of Biogen's Net Margin %

For the Drug Manufacturers - General subindustry, Biogen's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen's Net Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's Net Margin % distribution charts can be found below:

* The bar in red indicates where Biogen's Net Margin % falls into.



Biogen Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Biogen's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=19708.799/166951.914
=11.81 %

Biogen's Net Margin for the quarter that ended in Mar. 2024 is calculated as

Net Margin=Net Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=6528.967/38013.722
=17.18 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biogen  (MEX:BIIB) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Biogen Net Margin % Related Terms

Thank you for viewing the detailed overview of Biogen's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (MEX:BIIB) Business Description

Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (MEX:BIIB) Headlines

From GuruFocus

Biogen Inc at Stifel CNS Days (Virtual) Transcript

By GuruFocus Research 01-22-2024

Q1 2022 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Biogen Inc at Cowen Health Care Conference Transcript

By GuruFocus Research 01-22-2024

Biogen Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-22-2024

Q2 2022 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Biogen Inc at Stifel CNS Days (Virtual) Transcript

By GuruFocus Research 01-22-2024

Biogen Inc Analyst Q&A Call Transcript

By GuruFocus Research 01-22-2024

Q3 2022 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q2 2021 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024